Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

• Published in: Cardiology and Therapy Vol. 13; no. 1; pp. 117 - 135
• Main Authors: González-Moreno, Juan, Dispenzieri, Angela, Grogan, Martha, Coelho, Teresa, Tournev, Ivailo, Waddington-Cruz, Márcia, Wixner, Jonas, Diemberger, Igor, Garcia-Pavia, Pablo, Chapman, Doug, Gupta, Pritam, Glass, Oliver, Amass, Leslie
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2024; Springer; Adis, Springer Healthcare
• Subjects: Amyloidosis; Cardiology; Cardiomyopathy; Comorbidity; Development and progression; Heart diseases; Internal Medicine; Medicine; Medicine & Public Health; Mixed phenotype; NCT; NCT00628745; Original Research; Polyneuropathies; Polyneuropathy; Risk factors; THAOS; Transthyretin; United States; Mixed phenotype; THAOS; Amyloidosis; Polyneuropathy; Cardiomyopathy; Transthyretin
• ISSN: 2193-8261; 2193-6544; 2193-6544
• DOI: 10.1007/s40119-023-00344-3

Introduction Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described. Methods This study describes the mixed phenotype cohort in the Transthyretin Amyloidosis Outcomes Survey (THAOS). THAOS is an ongoing, longitudinal, observational survey of patients with ATTR amyloidosis, including both hereditary (ATTRv) and wild-type disease, and asymptomatic carriers of pathogenic transthyretin variants. Baseline characteristics of patients with a mixed phenotype (at enrollment or reclassified during follow-up) are described (data cutoff: January 4, 2022). Results Approximately one-third of symptomatic patients ( n  = 1185/3542; 33.5%) were classified at enrollment or follow-up as mixed phenotype (median age, 66.5 years). Of those, 344 (29.0%) were reclassified to mixed phenotype within a median 1–2 years of follow-up. Most patients with mixed phenotype had ATTRv amyloidosis (75.7%). The most frequent genotypes were V30M (38.9%) and wild type (24.3%). Conclusions These THAOS data represent the largest analysis of a real-world mixed phenotype ATTR amyloidosis population to date and suggest that a mixed phenotype may be more prevalent than previously thought. Patients may also migrate from a primarily neurologic or cardiologic presentation to a mixed phenotype over time. These data reinforce the need for multidisciplinary evaluation at initial assessment and follow-up of all patients with ATTR amyloidosis. Trial Registration ClinicalTrials.gov: NCT00628745.